A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2

Yoko Hasegawa, Nobuyuki Oyama, Keiko Nagase, Osamu Yokoyama, Yasuhisa Fujibayashi, Takako Furukawa, Yoichi Arai, Seiichi Saito

Research output: Contribution to journalArticlepeer-review

Abstract

An immunotracer, 125Habeled RM2 (125I-RM2) has been reported to be useful for nuclear imaging of prostate cancer. According to both in vitro and in vivo studies, the uptake of 125I-RM2 in the prostate cancer cells, PC-3 and LNCaP, increased 6 hours after incubation with the tracer. This tracer uptake was blocked when the tumor cells were pretreated with unlabelled RM2. In the tumor-bearing mice, the tracer uptake was higher than that of muscle tissue at 72 hours after the tracer injection. 125I-RM2 showed excellent prostate cancer cell targeting, both in vitro and in vivo. Accordingly, RM2 seems to be a candidate for use as a radioimmunotracer ligand for prostate cancer imaging.

Original languageEnglish
Pages (from-to)55-56
Number of pages2
JournalNishinihon Journal of Urology
Volume72
Issue number2
Publication statusPublished - 2010 Feb

Keywords

  • Immunotracer
  • Prostate cancer
  • RM2

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'A basic research of nuclear imaging for prostate cancer with monoclonal antibody rm2'. Together they form a unique fingerprint.

Cite this